Silexion Therapeutics Shares Surge On Positive Preclinical Pancreatic Cancer Data

$6M Capital Raise: Clinical-Stage RNAi Cancer Biotech Silexion Prices Share & Warrant Offering at $4.00

Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration